Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
1,408 results
  • Darbepoetin Alfa for Late-onset Anemia in Neonates with Rhesus Hemolytic Disease. [Journal Article]
    Indian J Pediatr. 2023 Feb; 90(2):184-186.Rv S, S R
  • Neonates with Rhesus hemolytic disease can present with anemia beyond 1 wk of age due to bone marrow suppression and low erythropoietin secretion. Erythropoietin stimulating agents (ESA) were tried to manage anemia in these neonates. Darbepoetin alfa (DA) is a long-acting ESA used to treat anemia in premature neonates and in children with chronic kidney disease or on cancer chemotherapy. The auth…
  • Diagnosis and Treatment of Myelodysplastic Syndromes: A Review. [Review]
    JAMA. 2022 09 06; 328(9):872-880.Sekeres MA, Taylor J
  • CONCLUSIONS: MDS are diagnosed in approximately 4 per 100 000 people in the United States and are associated with a 5-year survival rate of approximately 37%. Treatments are tailored to the patient's disease characteristics and comorbidities and range from supportive care with or without erythropoiesis-stimulating agents for patients with low-risk MDS to hypomethylating agents, such as azacitidine or decitabine, for patients with higher-risk MDS. Hematopoietic cell transplantation is potentially curative and should be considered for patients with higher-risk MDS at the time of diagnosis.
New Search Next